1. Search Result
Search Result
Results for "

monoclonal antibody

" in MCE Product Catalog:

96

Inhibitors & Agonists

3

Screening Libraries

8

Peptides

3

MCE Kits

97

Inhibitory Antibodies

Cat. No. Product Name Target Research Area
  • HY-P99003
    Human IgG4 kappa, Isotype Control

    Inhibitory Antibodies Inflammation/Immunology
    Human IgG4 kappa, Isotype Control, a human monoclonal antibody, is an isotype control for human IgG4κ antibody.
  • HY-P99001
    Human IgG1 kappa, Isotype Control

    Inhibitory Antibodies Inflammation/Immunology
    Human IgG1 kappa, Isotype Control, a human monoclonal antibody, is an isotype control for human IgG1κ antibody.
  • HY-P99002
    Human IgG2 kappa, Isotype Control

    Inhibitory Antibodies Inflammation/Immunology
    Human IgG2 kappa, Isotype Control, a human monoclonal antibody, is an isotype control for human IgG2κ antibody.
  • HY-P99037
    Nipocalimab

    M281

    Inhibitory Antibodies Inflammation/Immunology
    Nipocalimab (M281) is a fully human, recombinant, aglycosylated IgG1 monoclonal antibody. Nipocalimab is a human deglycosylated IgG1 anti-FcRn monoclonal antibody that binds with picomolar affinity to Fc receptor (FcRn) at both endosomal pH 6.0 and extracellular pH 7.6.
  • HY-P99016
    Enfortumab

    Inhibitory Antibodies Cancer
    Enfortumab is a monoclonal antibody targeting Nectin-4. Enfortumab can used for researching urothelial cancer.
  • HY-P9980
    Belantamab

    GSK2857914

    TNF Receptor Cancer
    Belantamab (GSK2857914) is a humanised IgG1 anti-BCMA (TNFRSF17) monoclonal antibody. Belantamab can be used in the synthesis of antibody-drug conjugate (ADC), Belantamab mafodotin.
  • HY-P9969
    Matuzumab

    EMD 72000

    EGFR Cancer
    Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth.
  • HY-P99049
    Sotigalimab

    Inhibitory Antibodies Cancer Inflammation/Immunology
    Sotigalimab, a CD40 agonistic monoclonal antibody, can be used for the research of metastatic pancreatic adenocarcinoma.
  • HY-P99022
    Gantenerumab

    Amyloid-β Neurological Disease
    Gantenerumab is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab can be used for Alzheimer's disease research.
  • HY-P99042
    Polatuzumab

    Inhibitory Antibodies Cancer
    Polatuzumab is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab can be used to synthesize Polatuzumab Vedotin, which is an antibody-drug conjugate (ADC) targeting CD79b .
  • HY-P99041
    Panitumumab

    ABX-EGF

    EGFR Cancer
    Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody. Panitumumab has an anti-tumor activity.
  • HY-P99027
    Ieramilimab

    LAG525; IMP701

    Inhibitory Antibodies Cancer
    Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules.
  • HY-P99057
    Varlilumab

    CDX-1127

    TNF Receptor Cancer
    Varlilumab (CDX-1127) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity.
  • HY-P99039
    Oleclumab

    MEDI9447

    CD73 Cancer
    Oleclumab (MEDI9447) is a human IgG1λ anti-CD73 monoclonal antibody that inhibits CD73 function. Oleclumab has an anti-tumor activity.
  • HY-P9963
    Blinatumomab

    Anatumomab

    Inhibitory Antibodies Cancer
    Blinatumomab (Anatumomab) is a bispecific monoclonal antibody which can specifically targets the CD19 antigen present on B cells. Blinatumomab can be used for the research of acute lymphoblastic leukemia.
  • HY-P99053
    Tralokinumab

    Interleukin Related Inflammation/Immunology
    Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD).
  • HY-P99040
    Onvatilimab

    JNJ-61610588

    PD-1/PD-L1 Cancer
    Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity.
  • HY-P9944
    Palivizumab

    MEDI 493

    RSV Infection
    Palivizumab (MEDI 493), a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection.
  • HY-P99021
    Galcanezumab

    LY 2951742

    CGRP Receptor Neurological Disease
    Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research.
  • HY-P99036
    Nesvacumab

    Inhibitory Antibodies Inflammation/Immunology Cardiovascular Disease
    Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1.
  • HY-P99051
    Tinurilimab

    BAY 1834942

    Inhibitory Antibodies Cancer Inflammation/Immunology
    Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors.
  • HY-P99028
    Ibalizumab

    TMB-355; TNX-355

    HIV Infection
    Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research.
  • HY-P99043
    Rovalpituzumab

    Notch Cancer
    Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC).
  • HY-P9967
    Aducanumab

    BIIB037

    Amyloid-β Neurological Disease
    Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.
  • HY-P99023
    Girentuximab

    G250; cG250

    Carbonic Anhydrase Cancer
    Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).
  • HY-P9961
    Ofatumumab

    Arzerra

    Inhibitory Antibodies Cancer
    Ofatumumab (Arzerra) is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes.
  • HY-P9976
    Isatuximab

    Apoptosis Cancer
    Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions.
  • HY-P9916
    Sarilumab

    Anti-Human IL6Rα, Human antibody

    Interleukin Related Inflammation/Immunology
    Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis.
  • HY-P99054
    Tusamitamab

    Inhibitory Antibodies Cancer
    Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative).
  • HY-P9952
    Belimumab

    LymphoStat B

    TNF Receptor Inflammation/Immunology
    Belimumab (LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research.
  • HY-P99110
    Lanadelumab

    SHP643; DX-2930

    Ser/Thr Protease Inflammation/Immunology
    Lanadelumab (SHP643) is a humanized IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema.
  • HY-P9924
    Ixekizumab

    LY2439821

    Interleukin Related Inflammation/Immunology
    Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis.
  • HY-P9972
    Spartalizumab

    PDR001

    PD-1/PD-L1 Cancer
    Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC).
  • HY-P9914
    Eculizumab

    Anti-Human C5, Humanized antibody

    Complement System Cardiovascular Disease
    Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research.
  • HY-P99031
    Mavrilimumab

    CAM 3001

    c-Fms Inflammation/Immunology Cardiovascular Disease
    Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death.
  • HY-P99052
    Tislelizumab

    PD-1/PD-L1 Cancer Inflammation/Immunology
    Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer.
  • HY-P9945
    Mepolizumab

    SB 240563

    Interleukin Related Inflammation/Immunology Cardiovascular Disease
    Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma.
  • HY-P99112
    Satralizumab

    Interleukin Related Cancer Inflammation/Immunology
    Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research.
  • HY-P9975
    Theralizumab

    TGN1412

    Inhibitory Antibodies Inflammation/Immunology
    Theralizumab (TGN1412) is a superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can be used for the research of rheumatoid arthritis.
  • HY-P99055
    Urelumab

    Inhibitory Antibodies Cancer Inflammation/Immunology
    Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab. Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL).
  • HY-P99048
    Sintilimab

    IBI308

    PD-1/PD-L1 Cancer Inflammation/Immunology
    Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer.
  • HY-P99009
    Batoclimab

    HBM9161; IMVT-1401

    Inhibitory Antibodies Inflammation/Immunology
    Batoclimab is a human anti-FcRn monoclonal antibody. Batoclimab can be used for the research of autoimmune diseases mediated by pathogenic IgG antibodies.
  • HY-108730
    Avelumab

    Anti-Human PD-L1, Human antibody; MSB 0010718C; MSB0010718C

    PD-1/PD-L1 Cancer Inflammation/Immunology
    Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
  • HY-P9908
    Adalimumab

    Anti-Human TNF-alpha, Human antibody

    TNF Receptor Inflammation/Immunology
    Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
  • HY-P9906
    Bevacizumab

    Anti-Human VEGF, Humanized antibody

    VEGFR Cancer
    Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
  • HY-P99108
    Penpulimab

    PD-1/PD-L1 Cancer Inflammation/Immunology
    Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities.
  • HY-P9913
    Rituximab

    Anti-Human CD20 type I, Chimeric antibody

    Inhibitory Antibodies Cancer Inflammation/Immunology
    Rituximab is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.
  • HY-P9909
    Ustekinumab

    Anti-Human IL-12/IL-23, Human antibody

    Interleukin Related Inflammation/Immunology
    Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
  • HY-P9908A
    Adalimumab (anti-TNF-α)

    TNF Receptor Inflammation/Immunology
    Adalimumab (anti-TNF-α) is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
  • HY-P9906A
    Bevacizumab (PBS)

    Anti-Human VEGF, Humanized antibody (PBS)

    VEGFR Cancer
    Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
  • HY-109539
    Gemtuzumab ozogamicin

    Inhibitory Antibodies Cancer
    Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of Calicheamicin. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia.
  • HY-P99113
    Inebilizumab

    ADC Cytotoxin Inflammation/Immunology
    Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research.
  • HY-P9910
    Obinutuzumab

    GA101; Anti-Human CD20 type II, Humanized antibody

    Inhibitory Antibodies Cancer
    Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
  • HY-P9912A
    Pertuzumab (PBS)

    EGFR Cancer
    Pertuzumab (PBS), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
  • HY-P9911
    Vedolizumab

    Anti-Human lymphocyte α4β7 integrin, Humanized antibody

    Integrin Inflammation/Immunology
    Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
  • HY-P9912
    Pertuzumab

    EGFR Cancer
    Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
  • HY-P9904
    Atezolizumab

    MPDL3280A

    PD-1/PD-L1 Apoptosis Autophagy Cancer
    Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
  • HY-P9913A
    Rituximab (anti-CD20)

    Inhibitory Antibodies Cancer Inflammation/Immunology
    Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.
  • HY-P9802
    Anti-Spike-RBD Single Domain mAb

    SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain antibody

    SARS-CoV Infection
    Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity.
  • HY-P9905
    Cetuximab

    C225

    EGFR Cancer
    Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.
  • HY-P9985
    Disitamab vedotin

    RC48

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.
  • HY-P99047
    Simtuzumab

    AB 0024; GS 6624

    Monoamine Oxidase Inflammation/Immunology
    Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab can be used for the research of primary sclerosing cholangitis (PSC).
  • HY-P9919
    Durvalumab

    MEDI 4736

    PD-1/PD-L1 Cancer
    Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.
  • HY-P99045
    Sacituzumab

    Inhibitory Antibodies Cancer
    Trastuzumab is a humanized IgG1 monoclonal antibody for anti-trophoblast cell-surface antigen 2 (anti-Trop-2). Sacituzumab has the potential for metastatic triple-negative breast cancer research.
  • HY-108739
    Idarucizumab

    BI 655075

    Inhibitory Antibodies Cardiovascular Disease
    Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis.
  • HY-P9907
    Trastuzumab

    Anti-Human HER2, Humanized antibody

    EGFR Cancer
    Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
  • HY-P9958
    Denosumab

    Immunoglobulin G2; Ranmark

    NF-κB Cancer
    Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of RANKL (TNFSF11). Denosumab can reduce the risk of vertebral, nonvertebral and hip fractures, also has anti-cancer activity.
  • HY-P9968
    Nimotuzumab

    EGFR Cancer
    Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor drug, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).
  • HY-P9923
    Benralizumab

    MEDI-563; BIW-8405

    Interleukin Related Apoptosis Inflammation/Immunology Cancer
    Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma.
  • HY-P9901
    Ipilimumab

    MDX-010; BMS-734016

    Inhibitory Antibodies Cancer
    Ipilimumab is a fully human monoclonal IgG1κ antibody against the cytotoxic T-lymphocyte antigen-4 (CTLA-4), an immune-inhibitory molecule expressed in activated T cells and in suppressor T regulatory cells.
  • HY-P9950
    Omalizumab

    Olizumab; rhuMab-E25

    Inhibitory Antibodies Inflammation/Immunology
    Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research.
  • HY-P99010
    Bemarituzumab

    FGFR Cancer
    Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research.
  • HY-P9911A
    Vedolizumab (anti-α4β7-integrin)

    Integrin Inflammation/Immunology
    Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
  • HY-P9934
    Abciximab

    C7E3

    Integrin Cardiovascular Disease
    Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors.
  • HY-P9801
    Anti-Spike-RBD mAb

    SARS-CoV-2 (2019-nCoV) Spike RBD antibody

    SARS-CoV Infection
    Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment.
  • HY-P9807
    Anti-SARS-CoV-2 Spike mAb (CR3022)

    SARS-CR3022; SARS-CoV-2 antibody-CR3022

    SARS-CoV Infection Inflammation/Immunology
    Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein.
  • HY-P9927
    Secukinumab

    AIN457

    Interleukin Related Inflammation/Immunology
    Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.
  • HY-P99058
    Zolbetuximab

    IMAB362

    Inhibitory Antibodies Cancer
    Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors.
  • HY-P9970
    Infliximab

    Avakine; CT-P13

    TNF Receptor Metabolic Disease Inflammation/Immunology Neurological Disease
    Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
  • HY-P99114
    Sugemalimab

    PD-1/PD-L1 Cancer
    Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research.
  • HY-P99019
    Fremanezumab

    TEV-48125

    CGRP Receptor Neurological Disease
    Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research.
  • HY-P9915
    Daratumumab

    Anti-Human CD38, Human antibody

    Inhibitory Antibodies Cancer Inflammation/Immunology
    Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
  • HY-P99109
    Zimberelimab

    PD-1/PD-L1 Cancer
    Zimberelimab is a fully human IgG4 anti-PD-1 monoclonal antibody with high affinity and selectivity. Zimberelimab shows antitumor activities and can be used for various cancers research including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma.
  • HY-P9978
    Toripalimab

    PD-1/PD-L1 Cancer
    Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma.
  • HY-P9948
    Alemtuzumab

    Campath-IH; Lemtrada; MabCampath

    Inhibitory Antibodies Cancer
    Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52, a glycoprotein expressed on the surface of most lymphoid, and to a lesser extent, myeloid cell types. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes.
  • HY-P9951
    Ranibizumab

    RG-6321

    VEGFR Cardiovascular Disease
    Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165). Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research.
  • HY-P9920
    Ramucirumab

    VEGFR Cancer
    Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor.
  • HY-P9805
    Anti-MERS-3A1 mAb

    MERS-3A1; MERS antibody-3A1

    SARS-CoV Infection
    Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor.
  • HY-P9803
    Anti-SARS-80R mAb

    SARS-80R; SARS antibody-80R

    SARS-CoV Infection
    Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells.
  • HY-P9806
    Anti-MERS-D12 mAb

    MERS-D12; MERS antibody-D12

    SARS-CoV Infection
    Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding.
  • HY-P9931
    Guselkumab

    CNTO 1959

    Interleukin Related Inflammation/Immunology
    Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research.
  • HY-P9949
    Reslizumab

    Sch 55700

    Interleukin Related Inflammation/Immunology
    Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively.
  • HY-P9928
    Alirocumab

    REGN 727; SAR 236553

    Ser/Thr Protease Metabolic Disease
    Alirocumab (REGN 727) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia.
  • HY-P99008
    Atibuclimab

    Inhibitory Antibodies Inflammation/Immunology
    Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist.
  • HY-108831
    Natalizumab

    Integrin Inflammation/Immunology
    Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses.
  • HY-P99111
    Golimumab

    CNTO-148

    TNF Receptor Apoptosis Interleukin Related Caspase Cancer Inflammation/Immunology
    Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research.
  • HY-P9971
    Camrelizumab

    SHR-1210

    PD-1/PD-L1 Cancer
    Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al.